| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 7278221 | Biological Psychology | 2018 | 40 Pages |
Abstract
Integrating the existing preclinical and clinical data on ghrelin antagonism, specifically at the GHS-R1A receptor in mesolimbic dopaminergic pathways, may reveal a new and innovative target for the treatment of alcohol dependence in the future.
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
Anne Koopmann, Rilana Schuster, Falk Kiefer,